|
Volumn 2, Issue 8, 2014, Pages 607-609
|
Why are there no good treatments for diabetic neuropathy?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
DULOXETINE;
PREGABALIN;
TAPENTADOL;
BIOLOGICAL MARKER;
AMPUTATION;
CLINICAL TRIAL (TOPIC);
CONFOCAL MICROSCOPY;
DIABETES MELLITUS;
DIABETIC NEUROPATHY;
FOOT ULCER;
GLYCEMIC CONTROL;
HUMAN;
MORTALITY;
NERVE FIBER;
NEUROPATHIC PAIN;
NOCICEPTION;
NOTE;
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
COST OF ILLNESS;
DIABETIC NEUROPATHIES;
DRUG EFFECTS;
HEALTH;
HEALTH CARE PLANNING;
MEDICAL RESEARCH;
METHODOLOGY;
PAIN;
PAIN MEASUREMENT;
PERIPHERAL NERVOUS SYSTEM DISEASES;
REPRODUCIBILITY;
BIOMARKERS;
BIOMEDICAL RESEARCH;
COST OF ILLNESS;
DIABETIC NEUROPATHIES;
GLOBAL HEALTH;
HEALTH PRIORITIES;
HUMANS;
PAIN;
PAIN MEASUREMENT;
PERIPHERAL NERVOUS SYSTEM DISEASES;
REPRODUCIBILITY OF RESULTS;
RESEARCH DESIGN;
|
EID: 84906937177
PISSN: 22138587
EISSN: 22138595
Source Type: Journal
DOI: 10.1016/S2213-8587(14)70067-1 Document Type: Note |
Times cited : (35)
|
References (10)
|